Online inquiry

IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14321MR)

This product GTTS-WQ14321MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFL7 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016215.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51162
UniProt ID Q9UHF1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14321MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11044MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ2103MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ5502MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ6158MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ7392MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ4819MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ6163MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ3414MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aALB03
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW